FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000375621> ?p ?o ?g. }

• W2000375621 endingPage "820" @default.
• W2000375621 startingPage "815" @default.
• W2000375621 abstract "Background. Multiple myeloma is considered to be a drug responsive disease; however, there is no cure for this disease and virtually all patients will develop drug resistance. One form of drug resistance that has been documented is the multidrug resistance phenotype or MDR. Methods. A randomized trial of the combination of vincristine, doxorubicin, and dexamethasone (VAD) and VAD plus oral verapamil (VAD/v) in drug refractory multiple myeloma patients was performed by the South-western Oncology Group. Verapamil was used as a chemosensitizing agent to attempt to overcome or prevent MDR and improve the therapeutic outcome. Results. Response rates between the two treatment arms were similar with an overall response rate of 41% for the VAD alone arm and 36% for the VAD/v arm. Overall survival of patients was also similar with a median survival of 10 months for the VAD arm and 13 months for the VAD/v arm. The toxicity profile was also similar for both treatments, with myelosuppression being the dose-limiting toxicity. No significant correlation was observed between expression of P-glycoprotein, serum verapamil levels, and response to therapy. Conclusions. No beneficial effect was observed from the addition of oral verapamil to the VAD chemotherapy regimen for the treatment of drug-resistant myeloma patients. More effective and less toxic chemosensitizers are needed to study the role of chemosensitizers in reversing MDR in the clinic. Cancer 1995;75:815-20." @default.
• W2000375621 created "2016-06-24" @default.
• W2000375621 creator A5029123414 @default.
• W2000375621 creator A5036980145 @default.
• W2000375621 creator A5056492087 @default.
• W2000375621 creator A5056603745 @default.
• W2000375621 creator A5057589827 @default.
• W2000375621 creator A5063294358 @default.
• W2000375621 creator A5071127912 @default.
• W2000375621 date "1995-02-01" @default.
• W2000375621 modified "2023-10-15" @default.
• W2000375621 title "A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study" @default.
• W2000375621 cites W1754065147 @default.
• W2000375621 cites W1972264308 @default.
• W2000375621 cites W2017239698 @default.
• W2000375621 cites W2026392633 @default.
• W2000375621 cites W2038933446 @default.
• W2000375621 cites W2042367294 @default.
• W2000375621 cites W2088419541 @default.
• W2000375621 cites W2099704297 @default.
• W2000375621 cites W2139330198 @default.
• W2000375621 cites W2163636540 @default.
• W2000375621 cites W2168070336 @default.
• W2000375621 cites W2301279425 @default.
• W2000375621 cites W2397577365 @default.
• W2000375621 cites W2404356933 @default.
• W2000375621 cites W2414723303 @default.
• W2000375621 cites W2437802176 @default.
• W2000375621 cites W2615953705 @default.
• W2000375621 cites W4298330584 @default.
• W2000375621 doi "https://doi.org/10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r" @default.
• W2000375621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7828131" @default.
• W2000375621 hasPublicationYear "1995" @default.
• W2000375621 type Work @default.
• W2000375621 sameAs 2000375621 @default.
• W2000375621 citedByCount "143" @default.
• W2000375621 countsByYear W20003756212012 @default.
• W2000375621 countsByYear W20003756212013 @default.
• W2000375621 countsByYear W20003756212014 @default.
• W2000375621 countsByYear W20003756212015 @default.
• W2000375621 countsByYear W20003756212016 @default.
• W2000375621 countsByYear W20003756212017 @default.
• W2000375621 countsByYear W20003756212018 @default.
• W2000375621 countsByYear W20003756212019 @default.
• W2000375621 countsByYear W20003756212020 @default.
• W2000375621 countsByYear W20003756212021 @default.
• W2000375621 countsByYear W20003756212022 @default.
• W2000375621 countsByYear W20003756212023 @default.
• W2000375621 crossrefType "journal-article" @default.
• W2000375621 hasAuthorship W2000375621A5029123414 @default.
• W2000375621 hasAuthorship W2000375621A5036980145 @default.
• W2000375621 hasAuthorship W2000375621A5056492087 @default.
• W2000375621 hasAuthorship W2000375621A5056603745 @default.
• W2000375621 hasAuthorship W2000375621A5057589827 @default.
• W2000375621 hasAuthorship W2000375621A5063294358 @default.
• W2000375621 hasAuthorship W2000375621A5071127912 @default.
• W2000375621 hasBestOaLocation W20003756211 @default.
• W2000375621 hasConcept C114851261 @default.
• W2000375621 hasConcept C121332964 @default.
• W2000375621 hasConcept C126322002 @default.
• W2000375621 hasConcept C133936738 @default.
• W2000375621 hasConcept C142424586 @default.
• W2000375621 hasConcept C143998085 @default.
• W2000375621 hasConcept C2776364478 @default.
• W2000375621 hasConcept C2776375370 @default.
• W2000375621 hasConcept C2776694085 @default.
• W2000375621 hasConcept C2776755627 @default.
• W2000375621 hasConcept C2777022698 @default.
• W2000375621 hasConcept C2778496288 @default.
• W2000375621 hasConcept C2779429289 @default.
• W2000375621 hasConcept C2781413609 @default.
• W2000375621 hasConcept C31760486 @default.
• W2000375621 hasConcept C519063684 @default.
• W2000375621 hasConcept C71924100 @default.
• W2000375621 hasConcept C86803240 @default.
• W2000375621 hasConcept C87355193 @default.
• W2000375621 hasConcept C89423630 @default.
• W2000375621 hasConcept C98274493 @default.
• W2000375621 hasConceptScore W2000375621C114851261 @default.
• W2000375621 hasConceptScore W2000375621C121332964 @default.
• W2000375621 hasConceptScore W2000375621C126322002 @default.
• W2000375621 hasConceptScore W2000375621C133936738 @default.
• W2000375621 hasConceptScore W2000375621C142424586 @default.
• W2000375621 hasConceptScore W2000375621C143998085 @default.
• W2000375621 hasConceptScore W2000375621C2776364478 @default.
• W2000375621 hasConceptScore W2000375621C2776375370 @default.
• W2000375621 hasConceptScore W2000375621C2776694085 @default.
• W2000375621 hasConceptScore W2000375621C2776755627 @default.
• W2000375621 hasConceptScore W2000375621C2777022698 @default.
• W2000375621 hasConceptScore W2000375621C2778496288 @default.
• W2000375621 hasConceptScore W2000375621C2779429289 @default.
• W2000375621 hasConceptScore W2000375621C2781413609 @default.
• W2000375621 hasConceptScore W2000375621C31760486 @default.
• W2000375621 hasConceptScore W2000375621C519063684 @default.
• W2000375621 hasConceptScore W2000375621C71924100 @default.
• W2000375621 hasConceptScore W2000375621C86803240 @default.
• W2000375621 hasConceptScore W2000375621C87355193 @default.
• W2000375621 hasConceptScore W2000375621C89423630 @default.

• next